Clinical Trial Update: Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating denosumab in patients with recurrent or refractory osteosarcoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Children's Oncology Group | Conditions: Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21